Association between the IFN-γ and IL-1 genetic polymorphisms and colorectal cancer in the Chinese Han population

Fei, Bao-Ying; Lv, Huo-Xiang; Cheng, Yongwei; Yang, Jiang-Ming

doi:10.1007/s12041-014-0354-3

Cited by 6 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, intrinsic mutations and polymorphisms in IL-1 genes have been implicated as well in many cancer types as reviewed by Khazim et al [ 79 ], though results from studies are sometimes conflicting, and the association is not always clear. Single and IL-1 gene-cluster polymorphisms have been suggested to be associated with cancers such as cervical [ 80 ] and ovarian cancer [ 81 ], MM [ 82 ], esophageal [ 83 ], colorectal cancer (CRC) [ 84 ], NSCLC [ 85 ], pancreatic cancer [ 86 ], prostate cancer [ 87 ], and gastric cancer [ 88 – 90 ].…”

Section: Il-1 Dysregulation and Its Contribution To Cancer And Tumorimentioning

confidence: 99%

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

2018

View full text Add to dashboard Cite

Interleukin-1 (IL-1) has long been known to be a key mediator of immunity and inflammation. Its dysregulation has been implicated in recent years in tumorigenesis and tumor progression, and its upregulation is thought to be associated with many tumors. Overexpression of the IL-1 agonists IL-1a and IL-1b has been shown to promote tumor invasiveness and metastasis by inducing the expression of angiogenic genes and growth factors. IL-1 blockers such as anakinra and canakinumab are already approved and widely used for the treatment of some autoimmune and autoinflammatory diseases and are currently being tested in preclinical and human clinical trials for cancer therapy. In this paper we review the most recent discoveries regarding the association between IL-1 dysregulation and cancer and present the novel IL-1 blockers currently being tested in cancer therapy and their corresponding clinical trials.

show abstract

Section: Il-1 Dysregulation and Its Contribution To Cancer And Tumorimentioning

confidence: 99%

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

2018

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) has been reported as one of the most frequently seen reasons of cancer morbidity in both economically developed and developing countries both in women and men (Du et al, ; Fei, Lv, Cheng, & Yang, ). The incidence and mortality of CRC in people of more than 65 years in age are much higher in females than those in males (Kim et al, ).…”

Section: Introductionmentioning

confidence: 99%

Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway

Tian

Shen

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is commonly known as one of the most prominent reasons for cancer-related death in China. Ras homolog enriched in brain (RHEB) and the mammalian target activity of rapamycin (mTOR) signaling pathway were found correlated with CRC, but their specific interaction in CRC was still to be investigated.Therefore, we explored whether RHEB gene silencing affected the cell proliferation, differentiation, and apoptosis by directly targeting the mTOR signaling pathway in cells previously harvested from CRC patients. A microarray analysis was subsequently conducted to investigate the relationship between RHEB and mTOR. Eighty-three adjacent normal tissues and CRC tissues were selected.Immunohistochemistry was carried out to detect the positive expression rates of RHEB and Ki-67 in the CRC tissues. Cells were then transfected with different siRNAs to investigate the potential effects RHEB would have on CRC progression.The expressions of RHEB, 4EBP1, ribosomal protein S6 kinase (p70S6K), proliferating cell nuclear antigen (PCNA), B cell lymphoma 2 (bcl-2), and bcl-2-associated X protein (bax) were determined and then the cell cycle, cell proliferation, and apoptotic rate were also measured. We identified RHEB and mTOR as upregulated genes in CRC.Cells treated with RHEB silencing showed a decreased extent of mTOR, p70S6K, 4EBP1 phosphorylation and expression of RHEB, Ki-67, mTOR, p70S6K, 4EBP1, bcl-2, and PCNA as well as decreased activity of cell proliferation and differentiation; although, the expression of bax was evidently higher. Collectively, our data propose the idea that RHEB gene silencing might repress cell proliferation and differentiation while accelerating apoptosis via inactivating the mTOR signaling pathway.

show abstract

“…In genetic studies on carcinogenesis, the role of IL-1β and related signalling molecules was described. Polymorphisms in the IL-1β locus that pushes the system into a pro-inflammatory mode were associated with a risk of gastric [31,88,89], cervical [90], ovarian [91], oesophageal [92], colon [93], pancreatic [94], prostate [95], lung cancers [96][97][98][99][100] and CRC [101]. In contrast, single-nucleotide polymorphisms associated with over-expression of IL-1Ra led to a better prognosis in patients with advanced CRC [102].…”

Section: The Role Of Il-1β In the Clinical Outcome Of Oncological Pat...mentioning

confidence: 99%

Pathogenetic role and clinical significance of interleukin‐1β in cancer

et al. 2022

View full text Add to dashboard Cite

In recent years, pro-oncogenic mechanisms of the tumour microenvironment (ТМЕ) have been actively discussed. One of the main cytokines of the TМЕ is interleukin-1 beta (IL-1β), which exhibits proinflammatory properties. Some studies have shown an association between an increase in IL-1β levels and tumour progression. The purpose of this review is to analyse the pathogenic mechanisms induced by IL-1β in the TМЕ, as well as the diagnostic significance of the presence of IL-1β in patients with cancer and the efficacy of treatment with IL-1β inhibitors.According to the literature, IL-1β can induce an increase in tumour angiogenesis due to its effects on the differentiation of epithelial cells, pro-angiogenic molecule secretion and expression of adhesion molecules, thus increasing tumour growth and metastasis. IL-1β is also involved in the suppression of anti-tumour immune responses. The expression and secretion of IL-1β has been noted in various types of tumours. In some clinical studies, an elevated level of IL-1β was found to be associated with low efficacy of anti-cancer therapy and a poor prognosis. In most experimental and clinical studies, the use of IL-1β inhibitors contributed to a decrease in tumour mass and an increase in the response to anti-tumour drugs.

show abstract

Association between the IFN-γ and IL-1 genetic polymorphisms and colorectal cancer in the Chinese Han population

Cited by 6 publications

References 18 publications

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice

Silencing of RHEB inhibits cell proliferation and promotes apoptosis in colorectal cancer cells via inhibition of the mTOR signaling pathway

Pathogenetic role and clinical significance of interleukin‐1β in cancer

Contact Info

Product

Resources

About